




The relative strengths and weaknesses of Xeris Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Xeris Biopharma Holdings Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 80% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	240,313
Cost of Goods Sold	0
Intangible Assets	110,937
Liabilities, Current	109,574
Liabilities, Non-Current	260,264
Other Assets	27,332
Other Compr. Net Income	0
Other Expenses	53,412
Other Liabilities	0
Other Net Income	-24,342
Other Revenues	291,845
Property and Equipment	4,945
Research and Development	31,165
Selling, General and Administrative Expense	182,372

Output Variable	Value in 1000 USD
Assets	383,527
Liabilities	369,838
Expenses	266,949
Revenues	291,845
Stockholders Equity	13,689
Net Income	554
Comprehensive Net Income	554
BaseVar	668,250
ECR before Limited Liability	8.1%
Economic Capital Ratio	149%